Completed
PHASE1
INTERVENTIONAL
NCT06039826
A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The main purpose of this study is to determine the effect of LY3437943 when administered subcutaneously on the levels of combined oral contraceptive (COC) ethinyl estradiol and drospirenone in the blood stream in postmenopausal female participants who are overweight or obese. The safety and tolerability of LY3437943 when administered with COC will also be evaluated. This study will last up to approximately 29 weeks for each participant.
Interventions
Name:
LY3437943
Type:
DRUG
Description:
Administered SC.
Name:
Ethinyl Estradiol
Type:
DRUG
Description:
Administered orally
Name:
Drospirenone
Type:
DRUG
Description:
Administered orally
Primary Outcomes
Measure:
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time zero to 24 Hours Postdose (AUC0-24) of Ethinyl Estradiol
TimeFrame:
Predose on Day 1 up to 144 days postdose
Description:
PK: AUC0-24 of Ethinyl Estradiol
Measure:
PK: Maximum Observed Concentration (Cmax) of Ethinyl Estradiol
TimeFrame:
Predose on Day 1 up to 144 days postdose
Description:
PK: Cmax of Ethinyl Estradiol
Measure:
PK: Time of Maximum Observed Concentration (Tmax) of Ethinyl Estradiol
TimeFrame:
Predose on Day 1 up to 144 days postdose
Description:
PK: Tmax of Ethinyl Estradiol
Measure:
PK: Area Under the Concentration Versus Time Curve from Time zero to 24 Hours Postdose (AUC0-24) of Drospirenone
TimeFrame:
Predose on Day 1 up to 144 days postdose
Description:
PK: AUC0-24 of Drospirenone
Measure:
PK: Maximum Observed Concentration (Cmax) of Drospirenone
TimeFrame:
Predose on Day 1 up to 144 days postdose
Description:
PK: Cmax of Drospirenone
Measure:
PK: Time of Maximum Observed Concentration (Tmax) of Drospirenone
TimeFrame:
Predose on Day 1 up to 144 days postdose
Description:
PK: Tmax of Drospirenone
Trial Information
NCT ID
NCT06039826
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE1
Sponsor
Eli Lilly and Company
Last Updated
December 15, 2025